Comparison of in-hospital mortality in children and adolescents with sickle cell disease in a resource-limited setting before and during the COVID-19 pandemic - 03/01/24
, Puepi Djike Yolande c, Kedy Mangamba Koum Daniele-Christiane a, Mbono Ritha Betoko a, b, Epee Patricia a, Hassanatou Iyawa a, b, Michael Budzi Ngenge c, Megoze Abigaelle d, Noukeu Njinkui Diomède e, Enyama Dominique e, Ntsoli Kofane Gaelle b, Jackson Juliana b, Ekotto Karen b, Mony Elimbi Jeanne Georgette b, Etame Moussinga Margaret b, Ekoe Doriane b, Calixte Ida Penda a
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
COVID-19 in children and adolescents with sickle cell disease (SCD) has variable presentations (from mild to severe disease), and the main symptoms are vaso-occlusive crises (VOC) and acute chest syndrome (ACS). We hypothesized that the desertion of hospitals due to the pandemic would lead to late arrival at the emergency room and an increased mortality. In this study, we sought to measure and compare the mortality of children with sickle cell disease before and during the COVID-19 pandemic.
Material and methods |
We conducted a retrospective cohort study at the sickle cell disease management center of Laquintinie Hospital in Douala (Cameroon). The study period was divided into two, i.e., from March 2019 to February 2020 (Pre-COVID-19) and from March 2020 to February 2021 (COVID-19). All administrative and ethical considerations were fully respected. Data were analyzed using SPSS 20.0.
Results |
Overall, 823 patients were admitted during the study period. Males represented 52.4% of the overall population, giving a sex ratio of 1.1:1. We admitted 479 patients during the pre-COVID-19 period versus 344 patients during the COVID-19 period, which is a 28.2% drop in admissions during the COVID-19 period. The mortality rate was 3.5% during the pre-COVID-19 period and 3.2% during the COVID-19 period (p>0.05). The most common causes of death were ACS (39.3%, n = 11), severe anemia (25.0%, n = 7), and VOC (17.9%, n = 5). ACS (adjusted odds ratio [aOR]=3.628, 95% confidence interval [CI], [1.645–7.005], p<0.001) was significantly associated with mortality.
Conclusion |
During the COVID-19 pandemic, although the consultation frequency decreased, the mortality rate of sickle cell disease patients remained unchanged.
Le texte complet de cet article est disponible en PDF.Keywords : COVID-19, Sickle cell disease, Mortality, Cameroon
Plan
Vol 31 - N° 1
P. 38-43 - janvier 2024 Retour au numéro
Article précédent
- Transition care to adolescent hepatology in a tertiary center for rare adult–child liver disease
- Nolwenn Laborde, Karl Barange, Chloé Girard, Clothilde Marbach, Christophe Bureau, Pierre Broué
- No lockdown for pediatric burns
- Aurélien Binet, Hugo Tartrou, Marie Bousquet, Anne Le Touze
Bienvenue sur EM-consulte, la référence des professionnels de santé.